JP3665360B2 - Active oxygen scavenger and composition containing the same - Google Patents
Active oxygen scavenger and composition containing the same Download PDFInfo
- Publication number
- JP3665360B2 JP3665360B2 JP09328694A JP9328694A JP3665360B2 JP 3665360 B2 JP3665360 B2 JP 3665360B2 JP 09328694 A JP09328694 A JP 09328694A JP 9328694 A JP9328694 A JP 9328694A JP 3665360 B2 JP3665360 B2 JP 3665360B2
- Authority
- JP
- Japan
- Prior art keywords
- active oxygen
- acid
- oxygen scavenger
- present
- cosmetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123973 Oxygen scavenger Drugs 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 21
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical compound COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims description 20
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 20
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 12
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 10
- 235000004883 caffeic acid Nutrition 0.000 claims description 10
- 229940074360 caffeic acid Drugs 0.000 claims description 10
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 229940079877 pyrogallol Drugs 0.000 claims description 10
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 claims description 8
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 32
- 239000001301 oxygen Substances 0.000 description 32
- 229910052760 oxygen Inorganic materials 0.000 description 32
- 239000000126 substance Substances 0.000 description 26
- JMFRWRFFLBVWSI-NSCUHMNNSA-N coniferol Chemical compound COC1=CC(\C=C\CO)=CC=C1O JMFRWRFFLBVWSI-NSCUHMNNSA-N 0.000 description 18
- 230000002000 scavenging effect Effects 0.000 description 18
- 235000013305 food Nutrition 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 229940119526 coniferyl alcohol Drugs 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- -1 polyoxyethylene stearic acid Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 208000035985 Body Odor Diseases 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040954 Skin wrinkling Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 0 *c(cc1O)ccc1O Chemical compound *c(cc1O)ccc1O 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010040904 Skin odour abnormal Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WZRRZVUZWWMSKH-UHFFFAOYSA-N n'-naphthalen-1-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.C1=CC=C2C(NCCN)=CC=CC2=C1 WZRRZVUZWWMSKH-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【産業上の利用分野】
本発明は活性酸素消去剤及びこれを含有する化粧料、医薬組成物、食用組成物に関する。
【0002】
【従来の技術】
一般的に、活性酸素が生体に及ぼす影響としては、コラーゲン線維の架橋や、DNA螺旋の部分開裂、連鎖的ラジカルの発生による組織の損傷が挙げられ、その結果として皮膚のシワや弾力消失、脱毛といった生体の老化、気管支喘息等のアレルギー反応の惹起とヒスタミン放出による炎症の惹起、虚血性疾患である心筋梗塞における平滑筋の損傷、肝臓障害などの疾患の悪化、また、脳組織の破壊による痴呆の誘発等が引き起こされることが知られている。更に、詳細な原因は不明であるがリューマチの発症にも活性酸素が関与していると言われている。
【0003】
従って、生体内において活性酸素の発生を抑制することは、これらの疾患を治療あるいは予防する点で非常に重要なことであり、このため、従来より生体内に発生した活性酸素を消去する作用のある物質の探索が広く行われてきた。
【0004】
例えば、この様な作用を有する薬剤として、従来より用いられてきたものとしては、天然物由来のものでは、脂溶性のトコフェロール(ビタミンE)、水溶性のアスコルビン酸(ビタミンC)が挙げられ、合成化合物では、BHT(ブチルヒドロキシトルエン)、BHA(ブチルヒドロキシアニソール)等が挙げられる。しかし、これらの薬剤は活性酸素消去作用が十分ではなく、合成化合物においては、BHTもBHAも発癌性の疑いが持たれており、何れも活性酸素消去剤としては実用的とは言い難かった。
【0005】
また、最近では、十分な薬効と安全性を求めて、生薬抽出物から活性酸素消去作用を有する物質を得ようとする試みも数多くなされており、例えば、特開昭60−224629号、特開昭61−24522号、特開平2−193930号、特開平2−243632号、特開平2−264727号、特開平3−153629号、特開平3−221587号、特開平4−69343号、特開平4−202138号、特開平4−247010号の各公報に記載の発明は、何れも生薬由来の活性酸素消去作用を有する物質を利用したものである。しかし、これらの生薬抽出物では、安全性に問題がないものの、活性酸素消去作用の点から言えば、未だ十分なものは得られていなかった。
【0006】
更に、生体内の酵素の一つスーパーオキシドデスムターゼ(SOD)を投与することにより、生体内に発生する活性酸素を消去する試みもなされてきているが、SODはタンパク質であるため、その入手が困難であるばかりでなく、消化されてしまうが故に、経口投与は不可能であり、また、注射による投与においても、血中半減期が短く満足の行くものではなかった。
【0007】
一方、2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物やその塩が、活性酸素を消去する作用を有することは全く知られていなかった。更に、化粧料、医薬品あるいは食品等に含有させて、上述した様々な疾患の予防や治療、老化の防止、改善に用いる試みはされていなかった。
【0008】
【発明が解決しようとする課題】
本発明は、上記観点からなされたものであり、生体内に発生する活性酸素を消去する作用を十分に有し、更に、安全性が高い活性酸素消去剤及びこれを含有する化粧料、医薬品、食品等の組成物を提供することを課題とする。
【0009】
【課題を解決するための手段】
本発明者らは上記課題を解決するために、活性酸素消去作用を指標に各種化合物を広くスクリーニングした結果、2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物が優れた活性酸素消去作用を有することを見出し、本発明を完成するに至った。
【0010】
すなわち本発明は、2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物及び/又はその生理的に許容される塩からなる活性酸素消去剤及びこれを含有する化粧料、医薬組成物、食用組成物である。
【0013】
以下、本発明を詳細に説明する。
【0014】
<1>本発明の活性酸素消去剤
本発明の活性酸素消去剤は、化1で表される2,6−ジメトキシフェノール、化2で表されるシリンゴ酸、化3で表されるカフェー酸、化4で表されるピロガロール、化5で表されるメチルシナペート、化6で表されるシリングアルデヒド、化7で表されるプロトカテキン酸、化8で表されるアセトシリンゴ、化9で表されるコニフェリルアルコールから選ばれる化合物及び/又はその生理的に許容される塩からなる。
【0018】
【化1】
【0019】
【化2】
【0021】
【化3】
【0022】
【化4】
【0024】
【化5】
【0025】
【化6】
【0027】
【化7】
【0028】
【化8】
【0030】
【化9】
【0031】
なお、上記化合物は何れも既知物質であり、一般的な製造方法により得られる。また、これらの化合物のほとんどは合成品が市販されているので、本発明においては、これら市販品を用いることも可能である。
【0032】
本発明の活性酸素消去剤には、この様な化1から化9で表される化合物の他にこの化合物の生理的に許容される塩を用いることもできる。この場合、化1から化9で表される化合物及びその塩の1種を単独で用いても、又は2種以上を混合して用いてもよい。
【0033】
また、この様な塩としては、生理的に許容されるものであれば特に限定はされないが、例えば、ナトリウム、カリウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニア、トリエチルアミン、トリエタノールアミン等のアミン類との塩、アルギニン、リジン等の塩基性アミノ酸類との塩等が例示できる。
【0034】
<2>本発明の活性酸素消去剤を含有する組成物
本発明の組成物は、上記活性酸素消去剤の1種あるいは2種以上を常法により配合したものであり、具体的には、化粧料、医薬品、食品等が例示できる。
【0035】
(1)化粧料
本発明の化粧料は、シワ、脱毛等の予防、改善、体臭等の好ましくない匂いの発生を防ぐ等の目的で、上記活性酸素消去剤を配合したものである。
【0036】
上記化粧料における本発明の活性酸素消去剤の配合量は特に限定されないが、化粧料全量に対して0.01〜10重量%の範囲で配合されることが好ましく、更に、0.1〜1重量%の範囲で配合されることがより好ましい。活性酸素消去剤の配合量が0.01%未満では、活性酸素消去剤が有するシワ改善、脱毛改善、体臭改善等の効果が十分に得られない場合があり、10重量%を越えて配合しても効果が頭打ちになり経済的でない場合が多い。
【0037】
本発明が適用される化粧料としては、剤型は特に限定されないが、例えば、化粧水、乳液、クリーム等の基礎化粧料、ファンデーション、アンダーメークアップ、白粉等のメークアップ化粧料、ヘアトニック、ヘアリキッド、シャンプー、リンス等の頭髪用化粧料等を挙げることができる。これらの化粧料は、上記活性酸素消去剤を配合する以外は、通常の化粧料と同様の方法で製造することができる。
【0038】
また、本発明の化粧料には、上記活性酸素消去剤の他に、化粧料に一般に用いられる各種成分、例えば、ワセリン、流動パラフィン等の炭化水素類、ホホバ油、カルナバワックス等のエステル類、オリーブ油、牛脂等のトリグリセライド類、ステアリルアルコール、ベヘニルアルコール等の高級アルコール類、ステアリン酸、ベヘン酸等の脂肪酸類、グリセリルモノステアレート、ポリオキシエチレンステアリン酸、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンステアリルエーテル等のノニオン界面活性剤、石鹸、硫酸エステル等のアニオン界面活性剤、ステアリルアミン等のカチオン界面活性剤、アルキルベタイン等の両性界面活性剤、グリセリン、プロピレングリコール等の多価アルコール類、各種粉末成分、保湿剤、増粘剤、色剤、香料、抗酸化剤、pH調整剤、キレート剤、防腐剤、あるいは紫外線防御剤、抗炎症剤、美白剤等を配合することができる。
【0039】
更に、本発明の化粧料には、本発明の活性酸素消去剤である2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物及び/又はその生理的に許容される塩以外に、SOD等の活性酸素消去作用を有する物質を配合してもよい。
【0040】
(2)医薬品
本発明の活性酸素消去剤を医薬品として製剤化する場合、剤型は特に限定されないが、例えば、注射剤、散剤、顆粒剤、錠剤、カプセル剤、液剤等、通常用いられている各種製剤に、通常の方法に従って剤型化することができる。また、剤型化に際しては、上記活性酸素消去剤以外に、賦形剤、結合剤、崩壊剤、滑沢剤、矯味矯臭剤、増量剤、被覆剤等の医薬品で通常用いられる任意成分を任意の量、用いることもできる。
【0041】
上記医薬品の投与量に関しては、疾患の種類、症状、患者の年令、体重等により異なるが、成人1人1日あたり、活性酸素消去剤の量として10mg〜1000mgを1回ないしは数回に分けて経口投与するか、5mg〜500mgを注射で投与するのが適当である。注射剤の投与方法としては、静脈内投与、動脈内投与、門脈内投与、腹腔内投与、筋肉内投与、皮下投与等が例示できる。
【0042】
(3)食品
本発明の活性酸素消去剤を食品に配合する場合、種々の食品へ、食品で通常用いられる任意成分と共に配合できる。例えば、キャンディーやグミ、ゼリーといった菓子類やジュースの様なドリンク類、パン等の主食が挙げられる。配合量は、食品の種類により異なるが、食品の味を損なわずに、且つ十分な活性酸素消去効果が期待できる0.01〜10重量%であることが好ましく、更に、0.1〜1重量%であることがより好ましい。
【0043】
【作用】
本発明の活性酸素消去剤として用いる、2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、及びコニフェリルアルコール、及びこれらの他に没食子酸、グアヤコール、メチルガレート、及びフェルラ酸を用いて、安全性及び活性酸素消去作用に関する試験を行った。
【0044】
なお、試験に用いた上記化合物は全てアルドリッチ製のものであった。
【0045】
(1)急性毒性試験(腹腔内投与)
5匹づつ13群のICR雄性マウス(体重25〜30g)の各群に、上記各化合物を生理食塩水に溶解して1000mg/kgの割合でそれぞれ腹腔内投与した。投与後14日に生死を判定したが何れの群においても死亡例を認めなかった。これより、本発明の活性酸素消去剤の腹腔内投与によるLD50値は1000mg/kgより大きく、安全性に優れていることがわかる。
【0046】
(2)急性毒性試験(経口投与)
6匹づつ13群のICR雄性マウス(体重25〜30g)の各群に、上記各化合物を生理食塩水に溶解して1000mg/kgの割合でそれぞれ経口投与した。投与後14日目に生死を判定したが何れの群においても死亡例を認めなかった。これより、本発明の活性酸素消去剤の経口投与によるLD50値は1000mg/kgより大きく、安全性に優れていることがわかる。
【0047】
(3)活性酸素消去作用の測定
化29に示す反応式に基づき、キサンチン−キサンチンオキシダーゼ(XOD)系により活性酸素の一つであるスーパーオキシドアニオン(O2 -)を発生させ、発生したO2 -の生成率を亜硝酸法により測定し、この値をキサンチンオキシダーゼ阻害率値で補正して活性酸素消去作用値を求めた。
【0048】
【化10】
【0049】
上記各化合物を各種モル濃度で含有する活性酸素消去剤水溶液0.1mLを、65mM燐酸2水素カリウム、35mMホウ酸ナトリウム、0.5mMEDTA2ナトリウム水溶液(以下、緩衝液Aという)0.2mL、0.5mMキサンチン溶液0.2mL、10mMヒドロキシルアミン塩酸塩水溶液0.1mL、純水0.2mLの混合液に、加えてよく撹拌し試験液とした。同様にして、活性酸素消去剤の代わりに純水0.1mLを用いたコントロールの溶液を作成した。
【0050】
上記試験液及びコントロール溶液に、キサンチンオキシダーゼを1μL/mL濃度で含有する緩衝液Aを0.2mL加えて撹拌した後、37℃で30分インキュベーションした。ブランクとして、上記と同様に調整された試験液及びコントロール溶液に、キサンチンオキシダーゼを含まない緩衝液Aを0.2mL加え、上記と同様に処理した溶液を用意した。
【0051】
この様にして得られた各溶液のそれぞれに、30μMのN−1−ナフチルエチレンジアミン塩酸塩、3mMのスルファニル酸、25%氷酢酸混液2mLを加え、30分間室温で放置した後、各溶液について550nmの吸光度で活性酸素の発生量を、295nmの吸光度で尿酸の発生量を測定した。
【0052】
得られた値を用いて、以下の式に基づき、活性酸素消去活性値を算出した。
【0053】
【数1】
活性酸素発生率=[(A550-3−A550-4)/(A550-1−A550-2)]×100
尿酸生成率=[(A295-3−A295-4)/(A295-1−A295-2)]×100
活性酸素消去活性=100−(活性酸素発生率/尿酸生成率)×100
但し、式中の記号は、表1に示す条件で調整された各溶液の吸光度の値とする。
【0054】
【表1】
【0055】
更に、上記方法で得られた活性酸素消去活性値を非線形最小自乗法プログラムにかけ、IC50値(M)を算出した。結果を表2に示す。
【0056】
【表2】
【0057】
この結果から明らかなように、本発明の活性酸素消去剤として用いる上記9種類の化合物は何れもIC50値が極めて低く、低濃度でも優れた活性酸素消去活性を有していることがわかる。
【0058】
本発明の活性酸素消去剤及びこれを含有する化粧料、医薬品、食品等の組成物は、その有効成分である2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物及び/又はその生理的に許容される塩の優れた活性酸素消去作用により、上述したような活性酸素が関与しているとされている、シワの形成、体臭の発生、脱毛、炎症、老人性痴呆、心筋梗塞等の虚血性疾患、あるいはアレルギー性疾患、肝臓障害、リューマチ等様々な疾病の治療や皮膚などの生体老化の改善に対して有効に働くものである。
【0059】
また、本発明の活性酸素消去剤及びこれを含有する化粧料、医薬品、食品等の組成物は、上記疾病や生体老化の予防のためにも有効に使用できる。これは、活性酸素消去作用を有する成分を、予め生体内に存在させることにより、生体内で発生した活性酸素を素早く消去し、無毒化することができるためである。
【0060】
【実施例】
以下に、2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド、プロトカテキン酸、アセトシリンゴ、コニフェリルアルコールから選ばれる化合物を活性酸素消去剤として含有する食品、医薬品、化粧料等の本発明の組成物の実施例を説明する。なお、以下に用いる配合量は、特にことわりのない限りすべて重量部である。
【0061】
また、本発明の実施例に活性酸素消去剤として配合した2,6−ジメトキシフェノール、シリンゴ酸、カフェー酸、ピロガロール、メチルシナペート、シリングアルデヒド及びコニフェリルアルコールは、全てアルドリッチ製のものであった。
【0062】
【実施例1】
キャンディー
表3のA成分を150℃で加熱溶解し120℃に冷却した後、B成分を添加し撹拌して均一にした。これを成形した後、冷却してキャンディーを得た。
【0063】
【表3】
【0066】
【実施例2〜4】
ジュース
表4の成分をよく撹拌可溶化し、滅菌、無菌充填、密閉してジュースを製造した。
【0067】
【表4】
【0068】
【実施例5】
ホットケーキ
表5の成分をよく混ぜ合わせ、油を引いたフライパンで焼き上げてホットケーキを作製した。
【0069】
【表5】
【0070】
【実施例6】
顆粒剤
表6のA成分をよく混合し、これに100mLの20%エタノール水溶液に溶解したB成分を練合しながら徐々に加え造粒した。これを40℃で2昼夜送風乾燥し、篩過、整粒し顆粒剤を得た。
【0071】
【表6】
【0074】
【実施例7、8】
化粧水
表7の成分を室温で撹拌可溶化し、化粧水を得た。
【0075】
【表7】
【0076】
【実施例9、10】
乳液
表8のA成分、B成分、C成分をそれぞれ80℃で加熱溶解し、A成分にB成分を加え、更にC成分を加え粗乳化し、ホモゲナイザーで均一に乳化し冷却して乳液を得た。
【0077】
【表8】
【0078】
【実施例11】
クリーム
表9のA成分、B成分、C成分をそれぞれ80℃に加熱溶解し、A成分にB成分を加え、更にC成分を加え、乳化し冷却してクリームを得た。
【0079】
【表9】
【0080】
【発明の効果】
本発明の活性酸素消去剤は活性酸素消去作用に優れ、更に安全性も高い。従って、これを配合した化粧料、医薬品、食品、あるいは飲料等の組成物は活性酸素が関与する疾患の予防と治療に長期にわたって有効に使用することができる。[0001]
[Industrial application fields]
The present invention relates to an active oxygen scavenger and cosmetics, pharmaceutical compositions and edible compositions containing the same.
[0002]
[Prior art]
In general, the effects of active oxygen on the living body include cross-linking of collagen fibers, partial cleavage of DNA helix, and tissue damage due to the generation of chain radicals. As a result, skin wrinkles and loss of elasticity, hair loss Aging of living organisms, induction of allergic reactions such as bronchial asthma and inflammation due to histamine release, smooth muscle damage in ischemic disease myocardial infarction, deterioration of diseases such as liver damage, and dementia due to destruction of brain tissue It is known that triggering and the like are caused. Furthermore, although the detailed cause is unknown, it is said that active oxygen is also involved in the development of rheumatism.
[0003]
Therefore, suppressing the generation of active oxygen in the living body is very important in terms of treating or preventing these diseases. For this reason, it has the effect of eliminating the active oxygen generated in the living body. The search for certain substances has been widely conducted.
[0004]
For example, as a drug having such an action, those conventionally used include those derived from natural products such as fat-soluble tocopherol (vitamin E) and water-soluble ascorbic acid (vitamin C). Examples of synthetic compounds include BHT (butylhydroxytoluene), BHA (butylhydroxyanisole), and the like. However, these agents are not sufficient in scavenging active oxygen, and in synthetic compounds, both BHT and BHA are suspected to be carcinogenic, and it has been difficult to say that both are practical as active oxygen scavengers.
[0005]
Recently, many attempts have been made to obtain a substance having an active oxygen scavenging action from a herbal extract in search of sufficient medicinal properties and safety. For example, Japanese Patent Application Laid-Open No. 60-224629 and Japanese Patent Application Laid-Open No. 60-224629. JP 61-24522, JP 2-193930, JP 2-243632, JP 2-264727, JP 3-153629, JP 3-221387, JP 4-69343, JP The inventions described in each of Japanese Patent Laid-Open Nos. 4-202138 and 4-247010 utilize substances having an action of scavenging active oxygen derived from herbal medicines. However, these herbal extracts have no safety problems, but in terms of the action of scavenging active oxygen, sufficient ones have not yet been obtained.
[0006]
Furthermore, attempts have been made to eliminate active oxygen generated in the living body by administering superoxide desmutase (SOD), which is one of the enzymes in the living body. Not only is it difficult, but it is also digested, so oral administration is not possible, and even administration by injection has a short blood half-life and is not satisfactory.
[0007]
On the other hand, a compound selected from 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapeate, syringaldehyde, protocatechinic acid, acetosyringo, and coniferyl alcohol has an action of eliminating active oxygen. That was completely unknown. Furthermore, no attempt has been made to use it in cosmetics, pharmaceuticals, foods, etc., for the prevention and treatment of the above-mentioned various diseases, prevention and improvement of aging.
[0008]
[Problems to be solved by the invention]
The present invention has been made from the above viewpoint, has a sufficient action of scavenging active oxygen generated in the living body, and has a high safety active oxygen scavenger, and cosmetics, pharmaceuticals containing the same, It is an object to provide a composition such as food.
[0009]
[Means for Solving the Problems]
In order to solve the above problems, the present inventors have extensively screened various compounds using active oxygen scavenging activity as an index. As a result, 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapate, syringaldehyde, The inventors have found that a compound selected from protocatechinic acid, acetosyl apple, and coniferyl alcohol has an excellent active oxygen scavenging action, and have completed the present invention.
[0010]
That is, the present invention is a compound selected from 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapeate, syringaldehyde, protocatechinic acid, acetosyringo, coniferyl alcohol and / or physiologically acceptable thereof. An active oxygen scavenger comprising a salt, and a cosmetic, a pharmaceutical composition and an edible composition containing the same.
[0013]
Hereinafter, the present invention will be described in detail.
[0014]
<1> Active oxygen scavenger of the present invention The active oxygen scavenger of the present invention is 2,6-dimethoxyphenol represented by Chemical Formula 1, symalic acid represented by Chemical Formula 2, caffeic acid represented by Chemical Formula 3, Pyrogallol represented by Chemical formula 4, Methyl cinnapeate represented by Chemical formula 5, Shilling aldehyde represented by Chemical formula 6, Protocatechinic acid represented by Chemical formula 7, Acetosyl apple represented by Chemical formula 8, Chemical formula 9 A compound selected from coniferyl alcohol and / or a physiologically acceptable salt thereof.
[0018]
[Chemical 1 ]
[0019]
[Chemical 2 ]
[0021]
[Chemical 3]
[0022]
[Formula 4]
[0024]
[Chemical formula 5]
[0025]
[Chemical 6]
[0027]
[Chemical 7]
[0028]
[Chemical 8]
[0030]
[Chemical 9]
[0031]
The above compounds are all known substances and can be obtained by a general production method. In addition, since most of these compounds are commercially available as synthetic products, these commercially available products can also be used in the present invention.
[0032]
In addition to the compounds represented by the chemical formulas 1 to 9 described above, physiologically acceptable salts of this compound can also be used for the active oxygen scavenger of the present invention. In this case, the compound represented by Chemical Formula 1 to Chemical Formula 9 and a salt thereof may be used alone or in combination of two or more.
[0033]
Such salts are not particularly limited as long as they are physiologically acceptable. For example, salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, and the like. And salts with amines such as ammonia, triethylamine, and triethanolamine, and salts with basic amino acids such as arginine and lysine.
[0034]
<2> Composition containing the active oxygen scavenger of the present invention The composition of the present invention comprises one or more of the above-mentioned active oxygen scavengers formulated in a conventional manner. Examples include foods, pharmaceuticals, and foods.
[0035]
(1) Cosmetics The cosmetics of the present invention contain the active oxygen scavenger described above for the purpose of preventing and improving wrinkles and hair loss and preventing the generation of unpleasant odors such as body odors.
[0036]
Although the compounding quantity of the active oxygen scavenger of this invention in the said cosmetics is not specifically limited, It is preferable to mix | blend in the range of 0.01 to 10 weight% with respect to cosmetics whole quantity, and also 0.1-1. More preferably, it is blended in the range of% by weight. If the amount of the active oxygen scavenger is less than 0.01%, the effects of the active oxygen scavenger such as wrinkle improvement, hair removal improvement, body odor improvement, etc. may not be obtained sufficiently. In many cases, however, the effect has reached its peak and is not economical.
[0037]
As the cosmetics to which the present invention is applied, the dosage form is not particularly limited. For example, basic cosmetics such as lotions, emulsions, creams, foundations, under-makeup, make-up cosmetics such as white powder, hair tonics, Examples include hair cosmetics such as hair liquid, shampoo, and rinse. These cosmetics can be produced in the same manner as ordinary cosmetics except that the active oxygen scavenger is blended.
[0038]
In addition to the active oxygen scavenger, the cosmetic of the present invention includes various components generally used in cosmetics, for example, hydrocarbons such as petrolatum and liquid paraffin, esters such as jojoba oil and carnauba wax, Triglycerides such as olive oil and beef tallow, higher alcohols such as stearyl alcohol and behenyl alcohol, fatty acids such as stearic acid and behenic acid, glyceryl monostearate, polyoxyethylene stearic acid, polyoxyethylene hydrogenated castor oil, polyoxyethylene stearyl Nonionic surfactants such as ethers, anionic surfactants such as soaps and sulfates, cationic surfactants such as stearylamine, amphoteric surfactants such as alkylbetaines, polyhydric alcohols such as glycerin and propylene glycol, various powders Ingredient, moisturizer, thickener Colorant, perfume, antioxidants, pH adjusting agents, chelating agents, preservatives, or ultraviolet protection agents, anti-inflammatory agents, can be blended whitening agent.
[0039]
Furthermore, the cosmetics of the present invention include 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapate, syringaldehyde, protocatechinic acid, acetosyringo, coniferyl alcohol, which are the active oxygen scavengers of the present invention. In addition to the compound selected from the above and / or physiologically acceptable salts thereof, a substance having an active oxygen scavenging action such as SOD may be blended.
[0040]
(2) Drugs When the active oxygen scavenger of the present invention is formulated as a drug, the dosage form is not particularly limited, but for example, injections, powders, granules, tablets, capsules, liquids and the like are usually used. Various preparations can be formulated according to conventional methods. In addition to the active oxygen scavenger described above, optional components commonly used in pharmaceutical products such as excipients, binders, disintegrants, lubricants, flavoring agents, bulking agents, coating agents, etc. are arbitrarily selected. Can also be used.
[0041]
The dosage of the above pharmaceuticals varies depending on the type of disease, symptoms, patient age, body weight, etc., but the amount of active oxygen scavenger per day for an adult is divided into 1 to several times. It is appropriate to administer by mouth or 5 mg to 500 mg by injection. Examples of the administration method of injections include intravenous administration, intraarterial administration, intraportal administration, intraperitoneal administration, intramuscular administration, and subcutaneous administration.
[0042]
(3) Food When the active oxygen scavenger of the present invention is blended in food, it can be blended into various foods together with optional ingredients usually used in food. For example, confectionery such as candy, gummi, and jelly, drinks such as juice, and staple foods such as bread. The blending amount varies depending on the type of food, but it is preferably 0.01 to 10% by weight, and further 0.1 to 1% by weight, which does not impair the taste of the food and can be expected to have a sufficient active oxygen scavenging effect. % Is more preferable.
[0043]
[Action]
2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapate, syringaldehyde, protocatechinic acid, acetosyringo, coniferyl alcohol, and other gallic acids used as the active oxygen scavenger of the present invention , Guaiacol, methyl gallate, and ferulic acid were used for safety and active oxygen scavenging tests.
[0044]
All the compounds used in the test were manufactured by Aldrich.
[0045]
(1) Acute toxicity test (intraperitoneal administration)
The above-mentioned compounds were dissolved in physiological saline and administered intraperitoneally at a rate of 1000 mg / kg in each group of 13 groups of ICR male mice (25-30 g body weight). Life or death was determined 14 days after administration, but no death was observed in any group. This shows that the LD 50 value by intraperitoneal administration of the active oxygen scavenger of the present invention is greater than 1000 mg / kg, which is excellent in safety.
[0046]
(2) Acute toxicity test (oral administration)
The above-mentioned compounds were dissolved in physiological saline and administered orally at a rate of 1000 mg / kg to each group of 13 ICR male mice (body weight 25-30 g). Life or death was determined on the 14th day after administration, but no death was observed in any group. This shows that the LD 50 value by oral administration of the active oxygen scavenger of the present invention is greater than 1000 mg / kg, and is excellent in safety.
[0047]
(3) Measurement of reactive oxygen scavenging action Based on the reaction formula shown in 29, a xanthine-xanthine oxidase (XOD) system generates superoxide anion (O 2 − ), which is one of active oxygen, and generates O 2. - measuring the production rate of the nitrous acid method, it was determined active oxygen scavenging action value by correcting the value with xanthine oxidase inhibition percentage value.
[0048]
[Chemical Formula 10]
[0049]
0.1 mL of an active oxygen scavenger aqueous solution containing each of the above compounds at various molar concentrations was added to 0.2 mL of 65 mM potassium dihydrogen phosphate, 35 mM sodium borate, 0.5 mM EDTA disodium aqueous solution (hereinafter referred to as buffer A), 0. It was added to a mixed solution of 0.2 mL of 5 mM xanthine solution, 0.1 mL of 10 mM hydroxylamine hydrochloride aqueous solution, and 0.2 mL of pure water, and stirred well to prepare a test solution. Similarly, a control solution was prepared using 0.1 mL of pure water instead of the active oxygen scavenger.
[0050]
0.2 mL of buffer solution A containing xanthine oxidase at a concentration of 1 μL / mL was added to the test solution and the control solution and stirred, and then incubated at 37 ° C. for 30 minutes. As a blank, 0.2 mL of buffer solution A not containing xanthine oxidase was added to a test solution and a control solution prepared in the same manner as described above, and a solution treated in the same manner as described above was prepared.
[0051]
To each of the solutions thus obtained, 30 μM N-1-naphthylethylenediamine hydrochloride, 3 mM sulfanilic acid, 2 mL of a 25% glacial acetic acid mixture was added and allowed to stand at room temperature for 30 minutes. The amount of active oxygen generated was measured with the absorbance of uric acid, and the amount of uric acid generated was measured with the absorbance of 295 nm.
[0052]
The active oxygen scavenging activity value was calculated based on the following formula using the obtained value.
[0053]
[Expression 1]
Active oxygen generation rate = [( A550-3 − A550-4 ) / ( A550-1 − A550-2 )] × 100
Uric acid production rate = [(A 295-3 −A 295-4 ) / (A 295-1 −A 295-2 )] × 100
Active oxygen scavenging activity = 100 - (active oxygen generation rate / uric acid production rate) × 100
However, the symbol in the formula is the absorbance value of each solution adjusted under the conditions shown in Table 1.
[0054]
[Table 1]
[0055]
Further, the active oxygen scavenging activity value obtained by the above method was applied to a non-linear least square method program to calculate an IC 50 value (M). The results are shown in Table 2.
[0056]
[Table 2]
[0057]
As can be seen from these results, the nine compounds used as the active oxygen scavenger of the present invention all have extremely low IC 50 values and have excellent active oxygen scavenging activity even at low concentrations.
[0058]
The active oxygen scavenger of the present invention and compositions such as cosmetics, pharmaceuticals, and foods containing the active oxygen scavenger are 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl synapate, and shilling aldehyde, which are active ingredients thereof. The active oxygen scavenging action of the compound selected from protocatechinic acid, acetosyl apple, coniferyl alcohol and / or its physiologically acceptable salt is considered to be involved in the active oxygen as described above. For the treatment of various diseases such as wrinkle formation, body odor, hair loss, inflammation, senile dementia, myocardial infarction, etc., or allergic diseases, liver disorders, rheumatism, etc. It works effectively.
[0059]
In addition, the active oxygen scavenger of the present invention and compositions such as cosmetics, pharmaceuticals and foods containing the same can be used effectively for the prevention of the above-mentioned diseases and bioaging. This is because the active oxygen generated in the living body can be quickly erased and detoxified by preliminarily allowing the component having the active oxygen eliminating action to exist in the living body.
[0060]
【Example】
Foods, pharmaceuticals containing, as an active oxygen scavenger, a compound selected from 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapeate, syringaldehyde, protocatechinic acid, acetosyringo, coniferyl alcohol , Examples of the composition of the present invention such as cosmetics will be described. The blending amounts used below are all parts by weight unless otherwise specified.
[0061]
In addition, 2,6-dimethoxyphenol, cimalic acid, caffeic acid, pyrogallol, methyl cinnapate, syringaldehyde and coniferyl alcohol blended as active oxygen scavengers in the examples of the present invention were all manufactured by Aldrich. .
[0062]
[Example 1]
The A component in Candy Table 3 was heated and dissolved at 150 ° C. and cooled to 120 ° C., and then the B component was added and stirred to make it uniform. After forming this, it cooled and the candy was obtained.
[0063]
[Table 3]
[0066]
[Examples 2 to 4 ]
Juice The ingredients in Table 4 were thoroughly agitated and solubilized, sterilized, aseptically filled, and sealed to produce juice.
[0067]
[Table 4]
[0068]
[Example 5 ]
Hot cake The ingredients in Table 5 were mixed well and baked in a frying pan from which oil was drawn to prepare a hot cake.
[0069]
[Table 5]
[0070]
[Example 6 ]
Granules The A component in Table 6 was mixed well, and the B component dissolved in 100 mL of 20% ethanol aqueous solution was gradually added and granulated while kneading. This was air-dried at 40 ° C. for two days and nights, sieved and sized to obtain granules.
[0071]
[Table 6]
[0074]
[Examples 7 and 8 ]
Skin lotion The ingredients in Table 7 were stirred and solubilized at room temperature to obtain a skin lotion.
[0075]
[Table 7]
[0076]
[Examples 9 and 10 ]
Emulsion A component, B component and C component in Table 8 are each heated and dissolved at 80 ° C., B component is added to A component, C component is further added, coarsely emulsified, uniformly emulsified with a homogenizer and cooled to obtain an emulsion. It was.
[0077]
[Table 8]
[0078]
[Example 11 ]
Cream A component, B component, and C component in Table 9 were each heated and dissolved at 80 ° C., B component was added to A component, C component was further added, emulsified and cooled to obtain a cream.
[0079]
[Table 9]
[0080]
【The invention's effect】
The active oxygen scavenger of the present invention is excellent in active oxygen scavenging action and is also safe. Therefore, compositions such as cosmetics, pharmaceuticals, foods, and beverages containing the same can be effectively used for a long period of time for the prevention and treatment of diseases involving active oxygen.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09328694A JP3665360B2 (en) | 1994-05-02 | 1994-05-02 | Active oxygen scavenger and composition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09328694A JP3665360B2 (en) | 1994-05-02 | 1994-05-02 | Active oxygen scavenger and composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07300412A JPH07300412A (en) | 1995-11-14 |
| JP3665360B2 true JP3665360B2 (en) | 2005-06-29 |
Family
ID=14078174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09328694A Expired - Fee Related JP3665360B2 (en) | 1994-05-02 | 1994-05-02 | Active oxygen scavenger and composition containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3665360B2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09255547A (en) * | 1996-03-22 | 1997-09-30 | Kao Corp | External preparation for skin |
| JPH1192410A (en) * | 1997-09-25 | 1999-04-06 | Naohiko Sato | Antioxidatively active substance |
| JP3849269B2 (en) * | 1997-12-26 | 2006-11-22 | 株式会社ノエビア | Topical skin preparation |
| GB9903216D0 (en) * | 1999-02-13 | 1999-04-07 | Zylepsis Ltd | Preservative compounds,compositions and methods of making and using the same |
| AU4147800A (en) * | 1999-04-13 | 2000-11-14 | Biosynergen, Inc. | Composition for preventing or treating dementia comprising hydroxycinnamic acid derivative or an extract of a plant of genus (angelicae) containing same |
| DE19934130A1 (en) * | 1999-07-23 | 2001-01-25 | Cognis Deutschland Gmbh | Cosmetic composition contains hydroxychavicol, effective as skin care active agent with e.g. antiaging action and as stabilizer against oxidative and microbial degradation |
| EA009281B1 (en) * | 2001-11-16 | 2007-12-28 | Катаникс Корпорейшн | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING AROMATIC ALDEHYDES CONTAINING OXYGROUP |
| US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
| DE10260955A1 (en) * | 2002-12-20 | 2004-07-08 | Henkel Kgaa | Use of steroid sulfatase inhibitors to reduce hair loss |
| JP4552459B2 (en) * | 2003-02-28 | 2010-09-29 | チッソ株式会社 | Polyamine-polyphenol hybrid and radical scavenger |
| JP5357372B2 (en) * | 2004-03-17 | 2013-12-04 | 花王株式会社 | Skin symptom improving agent |
| WO2007080669A1 (en) * | 2006-01-11 | 2007-07-19 | Microbiotech Inc. | Antiviral/antiinflammatory drug composition |
| JP5308042B2 (en) * | 2008-03-11 | 2013-10-09 | 新田ゼラチン株式会社 | Mango extract |
| PH12013501427B1 (en) | 2011-01-07 | 2019-02-13 | Allergan Inc | Melanin modification compositions and methods of use |
| JP5992309B2 (en) * | 2011-12-13 | 2016-09-14 | 大正製薬株式会社 | Composition for improving oral odor |
| JP2019104695A (en) * | 2017-12-11 | 2019-06-27 | 国立大学法人山口大学 | Vasospasm inhibitor, food, and food additive which contain benzoic acid derivative |
| CN114028376A (en) * | 2021-09-17 | 2022-02-11 | 武汉翼博济生生物科技有限公司 | Application of MG in preparation of NLRP3 pathway inhibitor for hyperuricemia nephropathy and/or gouty arthritis |
| JP7744642B1 (en) * | 2024-09-20 | 2025-09-26 | 国立大学法人 鹿児島大学 | vasospasm inhibitors |
-
1994
- 1994-05-02 JP JP09328694A patent/JP3665360B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07300412A (en) | 1995-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3665360B2 (en) | Active oxygen scavenger and composition containing the same | |
| JPH03190809A (en) | Skin external preparation | |
| KR101383217B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| JP2000229832A (en) | Skin lotion | |
| JP2937446B2 (en) | Blackening agent to prevent gray hair | |
| JPH09208484A (en) | Active oxygen-eliminator and composition containing the same | |
| JP2002193755A (en) | Anti-dandruff and Kayumi cosmetics for hair and hair wash | |
| JP3290291B2 (en) | Active oxygen scavenger and composition containing the same | |
| JP2008019180A (en) | Lipase inhibitor, horney plug formation inhibitor, pore conspicuousness inhibitor and pimple inhibitor | |
| JPH11269034A (en) | Skin prepafation for external use for improving acne | |
| JPH11139951A (en) | Cosmetics | |
| JP3668538B2 (en) | Active oxygen scavenger and composition containing the same | |
| JPH0948732A (en) | Activated oxygen scavenging agent and composition containing the same | |
| JP5429851B2 (en) | Active oxygen scavenger, skin external preparation and cosmetic using the active oxygen scavenger | |
| JP4669595B2 (en) | External agent for preventing and treating acne vulgaris and cosmetics containing the external agent | |
| JP2788166B2 (en) | Composition for eliminating active oxygen | |
| JP3495085B2 (en) | Active oxygen scavenger and composition containing the same | |
| JP2005200357A (en) | Hair restoration | |
| JPH02221213A (en) | Skin cosmetic | |
| JPH09118630A (en) | Active oxygen scavenger | |
| JP2001131025A (en) | Cosmetic for scalp and hair | |
| JP2811479B2 (en) | Hair restoration | |
| JP3808417B2 (en) | Hair nourishing | |
| JP2003206483A (en) | Antioxidant and external preparation for skin | |
| JPS6322506A (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050401 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |